Tafamidis ATTR Cm denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tafamidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Step Therapy for Tafamidis — and Why You Can Appeal

Step-therapy (also called "fail-first") denials for tafamidis in ATTR-CM are among the most clinically contested denials in cardiology. UHC's policy may require documentation that you have tried or been evaluated for less costly therapies before approving tafamidis. However, ATTR-CM is a distinct cardiomyopathy with a specific mechanism; many standard heart-failure medications do not stabilize transthyretin and may not satisfy a true clinical equivalent. Your prescriber can make this argument explicitly.

This is appealable — and often successfully — when your cardiologist documents why the step-therapy requirement cannot be safely applied to ATTR-CM physiology, or why prior therapies were tried and were insufficient.

## Federal Appeal Rights

• ACA §2719 / ERISA §503 give you the right to an internal appeal and, if denied, an independent external review.
• File your internal appeal within 180 days of the denial notice.
• The external-review window is approximately 4 months after final internal denial.
• Expedited review (72 hours) is available given the progressive, life-threatening nature of ATTR-CM — request it.

## Appeal Timeline

1. Obtain the full denial letter and the operative coverage/step-therapy policy. 2. File a written internal appeal with clinical documentation. 3. UHC must respond within 30 days standard or 72 hours expedited. 4. If denied, escalate to external IRO review immediately.

## Documentation to Gather

• Diagnosis confirmation: ATTR-CM confirmed by nuclear scintigraphy, echocardiography, or biopsy; genetic testing result (hereditary vs. wild-type).
• Prior treatment history: Chart entries with dates, dosages, and outcomes for any heart-failure therapies already tried; documentation of inadequate response or intolerance.
• Clinical severity: Functional class, six-minute walk test results, hospitalization history, disease progression notes.
• Specialist letter: A detailed medical-necessity letter from your cardiologist explaining the mechanistic distinction of ATTR-CM and why tafamidis is the appropriate, guideline-supported therapy — referencing the relevant cardiology guideline organization (e.g., applicable ACC/AHA guidance) without needing to quote numbers.
• Step-therapy exception basis: Statement of any applicable state step-therapy exception law or plan exception provision.

## Criteria-Mapping Structure

Pull the exact step-therapy requirements from UHC's published coverage policy. Map each requirement to a chart fact:

| Step-Therapy Requirement | Documentation Response | |---|---| | Prior trial of [specified therapy] | [Chart note with dates and outcome] | | Diagnosis confirmed by [specified method] | [Diagnostic report] | | Exception criteria (if applicable) | [Prescriber attestation or state law citation] |

Verify eligibility criteria against the current FDA prescribing information at DailyMed and against UHC's current published coverage policy — both must be satisfied and documented in your chart before submission.